Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT (HYPHYCA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Caen, France, 14076
- Centre Francois Baclesse
-
Caen, France, 14000
- CHU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient 18 years old
- Patient referred for 18F-FDG PET
Exclusion Criteria:
- History of surgery or anal and / or perineal and / or pelvic radiotherapy, whatever the indication
- Patient deprived of liberty, under tutorship or curatorship
- Any associated socio-educational, medical or psychological condition that could compromise the patient's ability to participate in the study (eg illiteracy, mental retardation, etc.)
- Pregnant woman (classic contraindication of a PET scan)
- Opposition of the patient to participate in the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Description of predictive factors for physiological hypermetabolism of the anal canal in 18F-FDG PET / CT
Time Frame: Only at the day of inclusion, during an appointment for a TEP exam
|
Confrontation in participants of hypermetabolism of the anal canal in PET with: number of stool/day and consistency of stool, medical history (by Answers to the specific questionnaire designed for the study) |
Only at the day of inclusion, during an appointment for a TEP exam
|
|
PET analysis of hypermetabolism of the anal canal
Time Frame: Only at the day of inclusion, during an appointment for a TEP exam
|
Visual analysis of hypermetabolism of the anal canal on a 3-point scale: 0: no hypermetabolism
|
Only at the day of inclusion, during an appointment for a TEP exam
|
|
CT scan with measurement
Time Frame: Only at the day of inclusion, during an appointment for a TEP exam
|
measurement of the largest rectal diameter in mm.
|
Only at the day of inclusion, during an appointment for a TEP exam
|
|
CT scan with measurement
Time Frame: Only at the day of inclusion, during an appointment for a TEP exam
|
Visual assessment of the rectal capacity on a 3-point scale (0, 1, 2) and content characteristics (air, feces, air and feces).
|
Only at the day of inclusion, during an appointment for a TEP exam
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2017-A03545-48
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anal Cancer
-
NCT05130073CompletedAnal Squamous Cell Carcinoma | Stage III Anal Cancer AJCC v8 | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8 | Stage 0 Anal Cancer AJCC v8
-
NCT03690921CompletedStage III Anal Cancer AJCC v8 | Anal Canal Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8
-
NCT04166318Active, not recruitingAnal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Anal Canal Squamous Cell Carcinoma | Anal Margin Squamous Cell Carcinoma | Stage I Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8
-
NCT05060471CompletedAnal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage I | Anal Canal Cancer Stage II | Anal Canal Cancer Stage III
-
NCT03233711Active, not recruitingAnal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Stage III Anal Cancer AJCC v8 | Anal Margin Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8
-
NCT07112690RecruitingStage IIIB Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage 0 Anal Cancer AJCC v8 | Localized Anal Carcinoma | Localized Anal Margin Carcinoma
-
NCT04444921Active, not recruitingAnal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Metastatic Anal Squamous Cell Carcinoma | Recurrent Anal Squamous Cell Carcinoma | Stage III Anal Cancer AJCC v8 | Stage IV Anal Cancer AJCC v8 | Unresectable Anal Squamous Cell Carcinoma
-
NCT02560298Active, not recruitingAnal Squamous Cell Carcinoma | Anal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Metastatic Anal Canal Carcinoma | Recurrent Anal Canal Carcinoma | Stage IIIB Anal Canal Cancer | Stage IV Anal Canal Cancer
-
NCT04046133Active, not recruitingAnal Cancer Stage III A | Anal Cancer Stage III B
-
NCT02314169Active, not recruitingStage IV Anal Cancer AJCC v8 | Anal Canal Squamous Cell Carcinoma | Metastatic Anal Canal Carcinoma
Clinical Trials on questionnary
-
NCT04385121CompletedDepression | Covid-19 | Stress Disorders, Post-Traumatic | Anxiety
-
NCT05617781CompletedPost-traumatic Stress Disorder | Mental Disorder | Empathy
-
NCT05701020CompletedSexual Dysfunction | Epidemiology
-
NCT04000802CompletedDecision Making | Quality of Health Care | Patient Care Team | Neoplasms/Therapy
-
NCT06448260CompletedWalking, Difficulty | Amputation, Surgical
-
NCT01782248UnknownAlzheimer Disease | Fronto-temporal Lobar Dementia
-
NCT03801018UnknownAssisted Reproductive Techniques
-
NCT05400200CompletedStress Disorders, Post-Traumatic